Thyrocare Technologies Ltd · NSE:THYROCARE

Thyrocare Technologies — Q4 FY2020 Earnings Presentation

19 slides from Thyrocare Technologies's earnings presentation, May 25, 2020

1. Slide 1: Dorai Digitally Ramjee 19:30:52 +05'30'

   Dorai Digitally signed by Dorai Ramjee Ramjee 19:30:52 +05'30' Date: 2020.05.25

2. Slide 2: Disclaimer

   Disclaimer This presentation is for information purposes only and it contains general background information about the Company’s activities. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements on the basis of any subsequent development, informatio

3. Slide 3: Standalone Annual Financial Performance - Thyrocare

   Standalone Annual Financial Performance - Thyrocare

4. Slide 4: Highlights - Standalone Annual Financial Performance - Thyrocare

   Highlights - Standalone Annual Financial Revenue from operations (in crore) Performance - Thyrocare Revenue from operations FY-20 - Rs. 400.00 crore (+8%) 400.0 [FY-19 - Rs. 370.28 crore] 370.3 Samples served FY-20 – 1.92 crore (+3%) [FY-19 – 1.88 crore] Investigations performed FY-20 – 11.04 crore

5. Slide 5: Highlights – Standalone Financial Performance – Thyrocare (Continued..)

   Highlights – Standalone Financial Performance – Thyrocare (Continued..) EBITDA FY-20 - Rs. 166.72 crore (+13%) [EBITDA margin 41.7%] [FY-19 – Rs. 148.14 crore] (EBITDA margin 40%) Normalized EBITDA FY-20 – Rs. 168.41 crore (EBITDA margin 42%) – adjusted for CSR, Provision for bad debts & IndAS 116 [

6. Slide 6: Thyrocare – Revenue, number of samples, tests

   Thyrocare – Revenue, number of samples, tests. Particulars FY-16 FY-17 FY-18 FY-19 FY-20 YOY CAGR Revenue from Operations (in crore) 225.42 285.98 331.79 370.28 400.00 8% 17% Number of samples (in thousands) 11,596.70 14,284.39 16,328.42 18,755.28 19,217.76 2% 16% Number of tests (in thousands) 61,5

7. Slide 7: Annual Financial Performance - Nueclear

   Annual Financial Performance - Nueclear

8. Slide 8: Highlights - Annual Financial Performance - Nueclear

   Highlights -Annual Financial Performance - Nueclear Revenue from operations (in crore) 34.09 Revenue from operations FY-20 - Rs. 34.09 crore (4%) [FY-19 - Rs. 32.64 crore] 32.64 Revenue from imaging services FY-20 - Rs. 31.49 crore (+4%) [FY-19 - Rs. 30.33 crore] Revenue from sale of FDG FY-20 - Rs.

9. Slide 9: Highlights – Annual Financial Performance – Nueclear (Continued..)

   Highlights – Annual Financial Performance – Nueclear (Continued..) EBITDA FY-20 - Rs. 5.06 crore (EBITDA margin 15%) [FY-19 - Rs. 5.0 crore (15%)] FY-19 13.4% 8.6% 57.4% 5.2% 15.3% FY-20 13.9% 9.3% 50.6% 11.5% 11.1% FDG & consumable costs Employee costs Other operating costs CMC EBITDA *Adjusted for

10. Slide 10: Nueclear – Revenue and number of scans

    Nueclear – Revenue and number of scans Particulars FY-16 FY-17 FY-18 FY-19 FY-20 YOY CAGR Revenue from Operations (in crore) 15.55 18.30 24.52 32.64 34.09 4% 29% Revenue from PET CT scans 15.55 18.30 22.71 29.65 31.49 6% 27% Number of PETCT scans 15,940 18,530 22,159 29,274 25,632 -12% 18% Revenue f

11. Slide 11: Consolidated Annual Financial Performance - Thyrocare

    Consolidated Annual Financial Performance - Thyrocare

12. Slide 12: Highlights – Annual Financial Performance - Consolidated

    Highlights – Annual Financial Performance - Revenue from operations (in crore) Consolidated 433.2 Revenue from operations FY-20 - Rs. 433.2 crore (+8%) [FY-19 - Rs. 402.9 crore] 402.91 Normalized EBITDA FY-20 - Rs. 173.18 crore (EBITDA margin 40%) [FY-19 - Rs. 160.37 crore (40%)] PAT FY-20 - Rs.95.0

13. Slide 13: Quarterly Financial Performance

    Quarterly Financial Performance

14. Slide 14: Highlights – Quarterly Standalone Thyrocare

    Revenue from operations (in crore) Standalone Thyrocare Highlights – Quarterly Financial Performance - 97.3 93.6 Thyrocare Revenue from operations Q4-20 - Rs. 93.63 crore (-3.7%) [Q4-19 - Rs. 97.27 crore] Samples processed Q4-20 – 0.45 crore (-7.4%) [Q4-19 – 0.49 crore] Investigations performed Q4-2

15. Slide 15: Highlights – Quarterly Financial Performance – Thyrocare (Continued..)

    Highlights – Quarterly Financial Performance – Thyrocare (Continued..) EBITDA Q4-20 - Rs. 29.30 crore (-10%) (EBITDA margin 31%) [Q4-19 – Rs. 34.10 crore] (EBITDA margin 35%) Normalized EBITDA Q4-20 – Rs. 33.70 crore (EBITDA margin 36%) [Q4-19 – Rs.36.53 crore (EBIDTA margin 38%)] PAT Q4-20 - Rs. 19

16. Slide 16: Highlights – Quarterly Standalone Nueclear

    Revenue from operations (in crore) Standalone Nueclear Highlights -Quarterly Financial Performance - Nueclear 8.33 Revenue from operations Q4-20 - Rs. 8.10 crore (-3%) [Q4-19 - Rs.8.33 crore] 8.10 Revenue from imaging services Q4-20 - Rs. 7.52 crore (-2%) [Q4-19 - Rs. 7.65 crore] Revenue from sale o

17. Slide 17: Highlights – Quarterly Financial Performance – Nueclear (Continued..)

    Highlights – Quarterly Financial Performance – Nueclear (Continued..) EBITDA Q4-20 - Rs. 1.32 crore (EBITDA margin 16%) [Q4-19 - Rs. 0.01 crore (-0.1%)] Normalized EBITDA Q4-20 – Rs. 1.01 crore (EBITDA margin 13%) [Q4-19 – Rs. 0.01 crore (EBIDTA margin (-0.1%)] Q4FY20 13.5% 8.9% 53.4% 11.7% 12.5% Q4

18. Slide 18: Consolidated Thyrocare

    Consolidated Thyrocare Revenue from operations Q4-20 - Rs. 101.5 crore (-4%) [Q4-19 - Rs. 105.6 crore] Normalized EBITDA Q4-20 - Rs. 35.02 crore (EBITDA margin 35%) [Q4-19 - Rs. 36.91 crore (35%)] PAT Q4-20 - Rs. – 16.49 crore (PAT margin - 16%) [Q4-19 - Rs. 17.1 crore (16%)] Q4FY20 26.8% 13.4% 27.3

19. Slide 19: Thank You

    Then You

Thyrocare Technologies — Q4 FY2020 Earnings Presentation on 6ix